Abstract: A microcapsule contains a biodegradable polymer and risperidone and has a sustained release property. The biodegradable polymer contained in the microcapsule has a molecular weight corresponding to 85% or more of an initial molecular weight (Mw) of the biodegradable polymer. A method of producing the microcapsule is also disclosed. The method of producing a microcapsule has (A) a step of preparing a first phase by mixing a solution of a biodegradable polymer and a solution of risperidone which are prepared separately, (B) a step of, immediately after the preparation of the first phase, mixing the first phase with a second phase being an aqueous phase to prepare an emulsion, and (C) a step of subjecting the resulting emulsion to in-water drying.
Abstract: Provided is a method for preventing postoperative adhesion of an organ in a wound site using the application of an antiadhesive material thereto. The antiadhesive material contains a poly-?-glutamic acid having a weight-average molecular weight of 600,000 to 13,000,000, or a kinematic viscosity at 37° C. of 2 cSt to 15 cSt when dissolved in distilled water at a concentration of 0.05% by mass and/or a salt thereof, as an effective ingredient. The antiadhesive material may be in a form such as powder, and therefore, for example, is easy to handle even in relatively localized surgery such as endoscopic surgery and can more reliably prevent adhesion.
Abstract: A novel hemostasis valve-equipped indwelling needle that is capable of discharging air in an internal flow path includes a cannula to be inserted percutaneously into a blood vessel on a distal end side thereof, a link connector on a proximal end side thereof, an internal flow path extending from the cannula to the link connector, and a hemostatic valve disposed inside the link connector. An air vent passage that allows the internal flow path to communicate with an external space is formed in the link connector further on the cannula side than the hemostatic valve, and a filter that allows gas to pass through but does not allow liquid to pass through is mounted in a compressed state on the air vent passage.
Abstract: [Object] To provide a means manufacturing a medical vial which contains a Type IA borosilicate glass as the raw material and in which the elution amount of silica into a high ionic strength solution decreases to be equal to or less than the silica elution amount in a Type IB borosilicate glass. [Solution] A method for manufacturing a medical vial is a method for manufacturing a medical vial including a fire blast process of applying a flame ejected from a point burner to a deteriorated layer generated on the inner surface of a vial, in which the vial is molded from a glass tube containing a Type IA borosilicate glass as the raw material and the molar ratio of oxides contained in the borosilicate glass satisfies ?=0.23±0.02 in ?=[(Na2O+K2O)—Al2O3]/B2O3 and satisfies ?=7.5±0.5 in ?=B2O3/Al2O3.
Abstract: Pharmaceutical composition particle capable of masking an unpalatable taste and improvement in dissolution properties, an orally disintegrating tablet containing the pharmaceutical composition particle, and a method for manufacturing a pharmaceutical composition particle. The pharmaceutical composition particle includes a core particle containing a drug and a water-soluble gelling swelling substance; and an outer layer which contains a water-insoluble substance and constitutes a coating provided on the outer side of the core particle. The method for manufacturing includes: pulverizing a water-soluble gelling swelling substance to have an average particle diameter of 15 ?m or less; a core particle manufacturing step of mixing the water-soluble gelling swelling substance pulverized and a drug to manufacture a core particle; and an outer layer formation step of coating the core particle with a water-insoluble substance on the outer side of the core particle.
Abstract: A myoelectric sensor for detecting myoelectric signals which accompany body movement includes: a wearing band that is elastic, expandable, and circular, and that is worn around a limb to surround the limb tightly; myoelectric detection units a plurality of which are disposed in the circumferential direction on the wearing band with intervals therebetween so as to cause each of a plurality of myoelectric detection electrodes to be in close contact with the surface of the limb, and which detect myoelectric signals from corresponding positions on the limb using the myoelectric detection electrodes; and connection cables that electrically connect mutually adjacent myoelectric detection units and thereby transmit the myoelectric signals. The connection cables each include a bent portion, the bent shape of which changes in response to changes in the distance between the mutually adjacent myoelectric detection units.
January 12, 2016
Date of Patent:
July 7, 2020
NIPRO CORPORATION, HARADA ELECTRONICS INDUSTRY CO., LTD.
Abstract: An apparatus for generating signal waveform for biological stimulation capable of generating and outputting a biological stimulation signal wave, from a signal existing in the external environment, reflected from the signal, which includes a signal input unit for inputting an external signal from the external environment and an output waveform generation unit for generating and outputting a first biological stimulation signal wave modulated with at least one of a frequency component, an envelope component and an amplitude component included in the external signal acquired by the signal input unit and/or synchronized with an output timing of the external signal.
June 8, 2018
June 25, 2020
NIPRO CORPORATION, HARADA ELECTRONICS INDUSTRY CO., LTD.
Abstract: A dose determination program for an erythropoiesis-stimulating agent that is executable by a computer. The program causes the computer to perform: obtaining a predetermined target hemoglobin concentration; obtaining a first concentration and a first dose in a stable state in which a hemoglobin concentration is stable at the first concentration by repeatedly administering the first dose a plurality of times, and calculating a second dose of the erythropoiesis-stimulating agent based on the obtained target hemoglobin concentration, the obtained first concentration, and the obtained first dose, the second dose of the erythropoiesis-stimulating agent being to be administered by a fixed amount.
Abstract: Provided is a method for aiding diagnosis of a neurodegenerative disease in a subject with a light physical burden. The method for aiding diagnosis of the neurodegenerative disease, comprising: a first assessment step of assessing a risk of the neurodegenerative disease based on an amount of homocysteine acid in a biological sample obtained from the subject; a second assessment step of assessing a risk of the neurodegenerative disease based on an amount of an inflammatory factor, a pituitary gland secretion, or an autonomic nerve secretion in the biological sample obtained from the subject or based on a measured value obtained from a brain image of the subject; and a step of determining whether the subject has the neurodegenerative disease based on the results of the first assessment and the second assessment.
Abstract: A blood circuit having a pressure measurement portion connected to a pressure measurement device includes: a first measurement portion provided downstream of a pumping segment; and a second measurement portion provided upstream of the pumping segment. The first measurement portion includes: a first housing having a tubular shape; and a first flexible membrane having a tubular shape and provided in the first housing. The second measurement portion includes: a second housing having a tubular shape; and a second flexible membrane having a tubular shape and provided in the second housing. A space between the first flexible membrane and the first housing is larger than a space between the second flexible membrane and the second housing in an initial state before permitting the blood to flow.
Abstract: A novel wipe set and a novel wiping method in which the wipe set is used are provided. With the wipe set comprising a first wipe impregnated with 50 to 200 mg of a sodium hypochlorite aqueous solution per gram of the wipe, a second wipe impregnated with 30 to 110 mg of a sodium thiosulfate aqueous solution per gram of the wipe, and a third wipe impregnated with 4 to 110 mg of a sodium hydroxide aqueous solution per gram of the wipe as well as by the wiping method in which the wipe set of the present invention is used, an anticancer agent spilled on a working table, for example, can be removed effectively.
April 9, 2012
Date of Patent:
May 12, 2020
MS DREAM CO., LTD., NIPRO CORPORATION
Mika Asano, Takeshi Oguro, Tomonori Imamura, Masaru Fujimura
Abstract: A blood purification apparatus that includes a blood purifier, a vascular access flow path, a cleaning solution flow path, and a drainage flow path. The blood purifier has an inner portion divided by a semi-permeable membrane into a first portion and a second portion. The vascular access flow path is connected to the blood purifier and is in communication with the first portion. The cleaning solution flow path is connected to the blood purifier and is in communication with the first portion. The drainage flow path is connected to the blood purifier and is in communication with the second portion. The cleaning solution flow path is provided with a blood pump capable of bidirectionally feeding a fluid. An open-close valve is provided in each of the vascular access flow path and the drainage flow path.
Abstract: The present invention provides a method for evaluating a processing deterioration level of a medical glass container, including (a) a step of imaging a surface of a medical glass container molded from a borosilicate glass tube to obtain an image, and (b) a step of analyzing a contrast of the image. The method is particularly useful to evaluate the amount of alkali substances which are deposited on the inner side surface of a medical glass container.
Abstract: [Object] To provide an ablation system capable of suppressing heat damages to the lumen intima. [Solution] An ablation system 10 has an ablation device 11 in which a balloon 21 is provided on the distal end side of a shaft 22 and an in-side tube 27 causing a fluid to flow into the balloon 21, the internal space of the shaft 22 causing a fluid to flow out of the balloon 21, and an optical fiber 29 guiding laser light into the balloon 21 are individually provided along the shaft 22, a laser light generating unit 12 emitting laser light to the optical fiber 29, and a fluid returning unit 13 returning a fluid into the internal space of the balloon 21. The ablation device 11 has a reflector 33 reflecting laser light emitted from the optical fiber 29 in the balloon 21, in which the reflector 33 is movable along the axial direction 191 in the balloon 21 and is rotatable in the axial direction 101 as the axis line.
Abstract: A pre-filled syringe includes: a cylindrical container, a front end-side gasket; a rear end-side gasket; an intermediate gasket partitioning an inside of the cylindrical container into a front chamber and a rear chamber; a plunger; a medical drug contained in the front chamber, and a liquid drug contained in the rear chamber. In a state where the plunger is pushed in, a bypass portion included in the cylindrical container faces a groove portion provided in the intermediate gasket, thereby allowing communication between the front chamber and the rear chamber therethrough, so that the medical drug and the liquid drug are mixed, and a liquid mixture is discharged. The pre-filled syringe further includes a movement limiting mechanism for limiting movement of the plunger such that a tail end of the rear end-side gasket does not reach the bypass portion.
Abstract: A syringe includes a barrel, a plunger, an injection needle, and an injection needle safety instrument. The injection needle safety instrument has a base portion fixed to the barrel, a cover portion which can cover a pointed end of a needle tube of the injection needle, and a hinge portion which pivotably couples the base portion and the cover portion. The cover portion is constructed to be pivotable between a first position at which the cover portion is held to the base portion as a first locked portion is locked by a locking portion of the base portion and a second position at which the cover portion covers the pointed end of the needle tube and is held to the injection needle as a second locked portion is locked to the same. The cover portion is tilted toward the barrel in the first position.
Abstract: To provide an autoserum-containing bone marrow cell culture system, whereby bone marrow cells, which are collected from a subject without using an anticoagulant, are subjected to an anticoagulation treatment using a medium in a liquid-tight state, cultured and then further cultured using the serum of said subject which is prepared in a liquid-tight state; an autoserum-containing bone marrow cell culture method; and a method for producing a medicinal composition which comprises, as the active ingredient, autoserum-containing cultured bone marrow cells. [Solution] An autoserum-containing bone marrow cell culture system for culturing bone marrow cells, which are collected from a subject without using an anticoagulant, using the serum of said subject, said system comprising a bone marrow cell suspension-storing device, a collected blood-storing device, an autoserum-acquiring device, and a bone marrow cell-culturing device.
Abstract: [Object] To provide a means manufacturing a medical glass container with less generation of a crack. [Solution] A method for manufacturing a medical glass container includes a first process of moving the tip of an ignited point burner 30 from a standby position where a flame 31 does not contact a vial 10 to a position where the tip of the ignited point burner 30 faces an opening 16 in the outside of the vial 10, a second process of inserting the tip of the point burner 30 into an internal space 14 of the vial 10, a third process of applying the flame 31 to an inner surface 15 of the vial 10 while holding the tip of the point burner 30 in the internal space 14, a fourth process of moving the tip of the point burner 30 to the outside from the internal space 14, and a fifth process of moving the tip of the point burner 30 from the position where the tip of the point burner 30 faces the opening 16 to the standby position.
Abstract: A syringe type ejection device capable of reducing an amount of residual liquid is provided. A syringe type ejection device includes: a barrel; a nozzle disposed to face the barrel; and a core inserted in the nozzle, the barrel having a large-diameter portion provided with a discharge space for discharging liquid, the nozzle being provided with a holding space for holding the core, the holding space being in communication with the discharge space, and the core being inserted in the discharge space.